Skip to content

Value Chain Analysis of the Diagnostic Medicine in Brazil.

Commercial Relationships

The value chain of the Diagnostic Medicine industry in Brazil is characterized by a complex web of commercial relationships spanning from the initial creation of diagnostic tools to the final delivery of patient results and subsequent financial flows. These relationships are multifaceted, involving transactions for products, services, and information, often governed by detailed contracts and regulatory frameworks.

At the foundational step of Research, Development, and Manufacturing, the primary commercial relationships involve manufacturers (both multinational and national) and their direct customers or distributors. Multinational manufacturers with a significant presence in Brazil, such as Roche Diagnostics, Siemens Healthineers, GE Healthcare, and Philips Healthcare, often operate through local subsidiaries or a network of large national distributors. These relationships are typically governed by long-term supply agreements, outlining product specifications, pricing, delivery schedules, and technical support obligations. National manufacturers like Vyttra Diagnósticos, Biocon Diagnóstica, and Gold Analisa Diagnóstica engage in similar supply relationships, though their distribution networks might be more focused regionally or through specialized channels. Research institutions and universities, while not primarily commercial entities in this context, may enter into licensing agreements with manufacturers to commercialize new diagnostic technologies or patents developed through their research. These agreements involve intellectual property rights transfer or usage permissions in exchange for royalties or licensing fees. The commercial interactions at this stage are predominantly Business-to-Business (B2B), focused on the procurement of high-value equipment and recurring purchases of consumables and reagents necessary for performing diagnostic tests.

Moving to Distribution and Commercialization, the commercial ties are centered around the flow of manufactured diagnostic products towards the service providers. Manufacturers sell to various types of distributors: large national wholesalers like Sullab, specialized distributors focusing on niche products or regions like DNEDX and Inopat, and sometimes directly to large diagnostic networks or hospital groups. The relationship between manufacturers and distributors is governed by distribution agreements, which grant distributors the right to sell products within a specific territory or market segment. These agreements detail pricing structures, payment terms, marketing support from the manufacturer, and responsibilities for logistics and inventory management. Distributors, in turn, sell to the diverse array of diagnostic service providers – from large laboratory networks like Dasa and Grupo Fleury to independent labs, hospitals, and clinics. These sales relationships can range from simple purchase orders for consumables to complex contracts for equipment acquisition, often including installation, training, and maintenance services. Manufacturer's direct sales teams engage in strategic B2B relationships with key accounts, negotiating volume discounts and tailored service packages. Representatives and brokers often act as intermediaries, facilitating connections between manufacturers or distributors and smaller service providers, typically working on commission-based models.

In the Diagnostic Service Provision step, the commercial relationships are primarily between the diagnostic service providers (laboratories, imaging centers, etc.) and their clients: patients, physicians (as referrers), hospitals, health insurance operators, and public health entities. The relationship with patients is a direct service provision, where the patient is the recipient and often partially or fully responsible for payment. With physicians, the relationship is based on trust and the quality of service and results, leading to referral patterns. Relationships with hospitals can involve integrated diagnostic departments or contracts for outsourcing specific tests or imaging services. The most significant and often contentious commercial relationships are with health insurance operators. Diagnostic providers contract with these operators (such as Bradesco Saúde, SulAmérica, Amil, and Hapvida) to be part of their accredited network, agreeing to perform tests for insured patients at negotiated reimbursement rates. These contracts are complex, detailing covered procedures, payment schedules, and administrative requirements. For the public sector (SUS), diagnostic providers, like Afip Medicina Diagnóstica in the outpatient network, engage in commercial relationships through public tenders and contracts with municipal, state, or federal health secretariats. These contracts define the scope of services, volume, and payment based on public health tables, which are often below private market rates.

The Healthcare Service Delivery and Utilization step involves the commercial interactions that facilitate the patient's access to and use of diagnostic services. Health insurance operators have commercial relationships with their beneficiaries (patients) through the sale of health plans, which promise coverage for diagnostic procedures according to the plan's terms. Their relationship with diagnostic providers is one of a payer for services rendered to their beneficiaries. Public health entities (Ministry of Health, state/municipal secretariats) have a mandate to provide access to diagnostic services for the SUS population, entering into contracts with private providers to meet demand where public infrastructure is insufficient. Companies engaging in occupational health have B2B contracts with diagnostic providers for employee testing programs. The commercial aspect here is driven by the financing mechanisms and the structures of healthcare access.

Finally, Financing and Reimbursement explicitly deals with the commercial flow of money. Government bodies are involved in allocating public funds to the SUS, effectively purchasing diagnostic services for the population. Health insurance operators are commercial entities whose business model relies on collecting premiums and managing the risk and cost of healthcare services, including diagnostics. Their commercial relationship with providers is that of a payer, involving claims processing and payment according to negotiated contracts. Patients have a direct commercial relationship when paying out-of-pocket for services or co-pays.

Throughout these steps, commercial relationships are heavily influenced by regulation and oversight. ANVISA regulates the products and facilities, requiring manufacturers and distributors to comply with strict standards and obtain registrations. ANS regulates the supplementary health market, impacting the contractual relationships and reimbursement models between health insurance operators and diagnostic service providers. These regulatory bodies, while not directly involved in commercial transactions, establish the mandatory framework within which all commercial activities must operate.

Products and Services Exchanged

Across the value chain of diagnostic medicine in Brazil, a diverse range of products and services are exchanged at each stage, facilitating the process from initial diagnosis to treatment planning.

In the Research, Development, and Manufacturing step, the primary outputs, and thus the products exchanged commercially, are the fundamental tools of diagnostics. This includes a vast array of In Vitro Diagnostic (IVD) products, such as chemical reagents, biological reagents, antibodies, calibrators, and control materials used in various laboratory tests (biochemistry, hematology, immunology, microbiology, molecular biology). Manufacturers also produce and exchange diagnostic equipment and instruments, ranging from automated analyzers for high-throughput testing in clinical chemistry and hematology to sophisticated molecular diagnostic platforms and point-of-care devices. For diagnostic imaging, manufacturers exchange large and complex machinery like MRI, CT scanners, X-ray machines, and ultrasound devices. In anatomical pathology, the exchanged products include specialized reagents, stains, antibodies for immunohistochemistry, and tissue processing equipment. Additionally, software and IT solutions, such as Laboratory Information Systems (LIS) and Picture Archiving and Communication Systems (PACS), are developed and exchanged, either bundled with equipment or as standalone products, to manage workflows and data. Services exchanged at this stage often include technical support, installation, training, and maintenance contracts for the complex equipment.

In the Distribution and Commercialization step, the core exchange involves the physical movement and sale of the diagnostic products manufactured in the previous step. Distributors exchange logistics services, including warehousing, inventory management, and transportation, often requiring specialized handling like cold chain management for temperature-sensitive reagents. They also provide sales and marketing services to promote manufacturer's products to diagnostic service providers. Technical expertise and support related to the products, especially for complex equipment, are also part of the service exchange. The commercial exchange is the sale of the diagnostic equipment, reagents, kits, and consumables from the distributor to the diagnostic service provider.

The Diagnostic Service Provision stage is where the actual diagnostic procedures are performed, and the primary exchange is that of diagnostic services. Clinical analysis laboratories exchange laboratory testing services across numerous disciplines, providing results for specific analytes, cell counts, presence of pathogens, immune markers, and genetic sequences. Diagnostic imaging centers exchange imaging examination services, producing detailed images of the internal body structures using various technologies. Anatomical pathology laboratories exchange tissue and cell analysis services, providing histological and cytological diagnoses, often including complex ancillary tests like immunohistochemistry and molecular pathology. Genetics and molecular diagnostics laboratories exchange specialized genetic and molecular testing services. Point-of-Care Testing providers exchange rapid diagnostic testing services, offering quick results for specific conditions outside traditional laboratory settings. Beyond the test itself, service providers exchange technical and scientific consulting with physicians, helping interpret results and select appropriate tests. The final, crucial product exchanged is the diagnostic report, containing the results and expert interpretation, which is delivered to the requesting physician and the patient.

In the Healthcare Service Delivery and Utilization step, the exchange shifts towards access and information flow within the broader healthcare system. Patients exchange payment (directly or through insurance) for access to diagnostic services. Physicians exchange diagnostic requests with service providers and receive back diagnostic reports and interpretations, which are then exchanged with the patient to inform treatment decisions. Health insurance operators exchange financial reimbursement with diagnostic providers in exchange for services rendered to their beneficiaries. Public health entities exchange funding and referrals with diagnostic providers to ensure access for the SUS population, receiving back service data and reports. The core "product" exchanged here is the diagnostic information and its integration into the patient's healthcare journey.

Finally, the Financing and Reimbursement step involves the exchange of money for services rendered. This includes the exchange of public funds from government entities to diagnostic providers within the SUS framework, the exchange of payments from health insurance operators to accredited providers based on negotiated rates and processed claims, and the exchange of direct payments from patients to providers. The services exchanged are financial in nature: payment processing, claims submission and adjudication, and financial reporting.

The Regulation and Oversight step involves the exchange of rules, standards, licenses, and inspection services from regulatory bodies like ANVISA and ANS. In return, manufacturers, distributors, and service providers exchange compliance information, documentation, and fees for licenses and registrations. Professional councils exchange licenses and ethical guidelines with healthcare professionals, who in turn exchange adherence to professional standards. Industry and professional associations exchange advocacy, market data, and best practices among their members and with regulatory bodies.

Business Models

The commercial relationships within the Brazilian Diagnostic Medicine value chain employ a variety of business models, reflecting the different interactions and economic incentives at each stage.

At the Research, Development, and Manufacturing level, manufacturers primarily operate on a product sales model. This involves developing, producing, and selling diagnostic equipment, reagents, and consumables. For large capital equipment, the model often includes direct sales to major clients (large lab networks, hospitals) with accompanying service contracts for installation, maintenance, and technical support. For reagents and consumables, manufacturers utilize both direct sales and wholesale/specialized distribution models, relying on distributors to reach a wider customer base. Licensing models are also present, where manufacturers license technology or patents from research institutions or other companies, paying royalties or fees for the right to use intellectual property. Some manufacturers may also operate on a reagent rental or cost-per-reportable-result model for equipment, where the equipment is provided at a reduced cost or free, and the revenue is generated through the recurring sale of proprietary reagents tied to the instrument.

In Distribution and Commercialization, the core business model is wholesale and retail distribution. Distributors purchase products from manufacturers at a lower price and sell them to diagnostic service providers at a markup, generating revenue from the volume and margin on product sales. Specialized distributors may command higher margins by offering niche products or specialized technical expertise. Logistics and value-added services, such as cold chain management, just-in-time delivery, and technical support, can be integrated into the distribution model, adding value and potentially increasing profitability. Consignment stock models, particularly for high-volume reagents, are common, where distributors or manufacturers place inventory at the customer site, and the customer only pays for the reagents as they are used. This model benefits the customer by reducing upfront inventory costs and benefits the distributor by ensuring a steady demand for their products.

The Diagnostic Service Provision step utilizes several key business models. The predominant model, especially with health insurance operators, is fee-for-service. Under this model, diagnostic providers are reimbursed a set fee for each test or procedure performed. The challenge with this model in Brazil is often negotiating favorable fees, as health insurance operators consistently seek to control costs. Contracts with health insurance operators are a major component of the business model for private laboratories and imaging centers, establishing the terms and rates for serving a large insured population. For the public sector (SUS), the model involves participating in public tenders and operating under government contracts, with reimbursement based on official SUS tables. These rates are notoriously low, impacting the financial sustainability of providers heavily reliant on the public system. Direct patient payment for services, often for specialized tests or for patients without insurance, operates on a fee-for-service basis but with prices set by the provider. Large laboratory networks like Dasa and Grupo Fleury employ a network model, leveraging economies of scale in purchasing, logistics, and test processing across multiple collection sites and central laboratories. They also increasingly offer B2B services to smaller laboratories or hospitals, acting as reference labs for specialized testing or providing laboratory management services, operating on service contract models. Vertical integration, where hospital groups like Rede D'Or São Luiz incorporate diagnostic services, represents an integrated care model, aiming for better coordination and cost control within their own system.

In Healthcare Service Delivery and Utilization, the business models relate to how access and payment are structured. Health insurance operators operate on a premium-based model, collecting regular payments from beneficiaries or employers to cover healthcare costs, including diagnostics. Their relationship with providers is a cost management and network management function. The public healthcare system (SUS) operates on a tax-funded model, where services are provided based on medical need, with funding allocated from government revenues. While theoretically free at the point of service for patients, the system's interaction with private providers is often contract-based through tenders. Companies providing occupational health services operate on a contractual service model with employers.

Finally, Financing and Reimbursement encompasses the operationalization of the financial flows. Health insurance operators have claims processing models to handle and pay invoices from diagnostic providers. They also engage in negotiation models with providers to determine reimbursement rates. The public system has budget allocation and payment models governed by government regulations and administrative processes. Direct patient payment is a simple transactional model.

Overall, the business models in the Brazilian diagnostic medicine value chain are a mix of product sales, service provision contracts (B2B and B2C), network management, and complex financing arrangements, heavily influenced by the dual public/private healthcare system and regulatory environment. Consolidation through mergers and acquisitions is a significant trend, particularly in the service provision step, aiming to create larger, more efficient entities with greater negotiating power.

Bottlenecks and Challenges

Despite its significant size and growth, the Diagnostic Medicine value chain in Brazil faces several critical bottlenecks and challenges that impact its efficiency, accessibility, and sustainability.

A major challenge lies in the high reliance on imported products in the Manufacturing and Distribution steps. Approximately 43.5% of the medical devices and IVD market in Brazil consists of imported goods. This dependence makes the entire value chain vulnerable to fluctuations in exchange rates, increasing the cost of equipment and reagents. It also exposes the market to global supply chain disruptions, potentially leading to shortages of essential diagnostic materials. The complexity and cost of logistics within a country the size of Brazil also pose a significant bottleneck in the Distribution step, particularly maintaining the cold chain for sensitive reagents across vast distances.

In the Regulation and Oversight domain, the bureaucratic and often lengthy process for product registration and approval by ANVISA remains a significant challenge for manufacturers and distributors. This can delay the introduction of new, innovative diagnostic technologies to the Brazilian market. Furthermore, diagnostic service providers face the challenge of complying with a complex and evolving regulatory landscape, including health surveillance regulations (like RDC 786) and data privacy laws (LGPD). Ensuring continuous compliance requires significant investment in quality control systems, infrastructure, and personnel.

Within the Diagnostic Service Provision and Financing and Reimbursement steps, the most prominent bottleneck is the pressure on reimbursement rates. Diagnostic providers, particularly those serving the supplementary health market, face intense pressure from health insurance operators to reduce costs, leading to stagnant or even declining reimbursement rates per procedure. These rates are often perceived by providers as insufficient to cover the rising costs of advanced equipment, reagents, and skilled labor, impacting profitability and the ability to invest in new technologies. Similarly, reimbursement rates within the SUS are considerably low, making it challenging for private providers to operate sustainably within the public system despite the high volume of exams. Delays in payment from both health insurance operators and public entities further exacerbate the financial strain on diagnostic service providers.

The Healthcare Service Delivery and Utilization step highlights challenges related to access disparities. While the supplementary system provides access for a significant portion of the population (~25%), the majority relies on the SUS, which often faces issues of underfunding, long wait times, and limited access to specialized or high-complexity diagnostic procedures, particularly in remote areas. The need for better integration of diagnostic information into a unified electronic health record system across different providers and health systems also remains a challenge, hindering continuity of care and efficient utilization of diagnostic data.

Operational challenges within Diagnostic Service Provision include the need for continuous investment in rapidly evolving technology. Diagnostic platforms become obsolete relatively quickly, requiring significant capital expenditure for upgrades or replacement. Attracting and retaining skilled professionals, such as pathologists, radiologists, biomedical scientists, and highly trained technicians, is another bottleneck, with potential labor shortages impacting service quality and capacity.

Finally, while market consolidation through mergers and acquisitions (M&A) is a trend aimed at creating efficiencies and stronger market players, it also raises concerns about potential market concentration and its impact on competition and pricing in the long term. The ability of smaller, independent laboratories to compete with large networks that benefit from economies of scale and greater negotiating power is a challenge for market diversity.

In summary, the key bottlenecks and challenges in the Brazilian Diagnostic Medicine value chain stem from a complex interplay of import dependency, logistical hurdles, regulatory burdens, intense pressure on reimbursement rates, access disparities, the need for continuous technological investment, labor shortages, and the evolving market structure driven by consolidation. Addressing these challenges requires coordinated efforts from government, regulatory bodies, payers, providers, and industry players.

References

  • Mordor Intelligence: Tamanho do mercado de diagnóstico in vitro do Brasil e análise de ações – Tendências e previsões de crescimento (2024 - 2029).
  • Vyttra Diagnósticos: soluções diagnósticas sem fronteiras. https://vyttra.com.br/
  • Shift: Tendências na medicina diagnóstica para 2025: inovação, eficiência e foco no paciente. https://medical.shift.com.br/tendencias-medicina-diagnostica-2025/
  • Associação Brasileira de Medicina Diagnóstica (Abramed): Pesquisa revela que brasileiros realizaram 2,4 bilhões de exames de diagnóstico em 2023.
  • Saúde Business: Medicina diagnóstica: perspectivas otimistas para o próximo ano. https://www.saudebusiness.com/gestao/medicina-diagnostica-perspectivas-otimistas-para-o-proximo-ano
  • Biocon Diagnósticos. https://biocon.com.br/
  • Sullab - Diagnósticos Clínicos. https://www.sullab.com.br/
  • Mobilemed: Tendências e desafios da Medicina Diagnóstica. https://mobilemed.com.br/tendencias-e-desafios-da-medicina-diagnostica/
  • Conrad: Perspectivas da medicina diagnóstica para 2025. https://conradweb.com.br/perspectivas-da-medicina-diagnostica-para-2025/
  • FGV EAESP: Impacto Da Criação Da Associação Brasileira De Medicina Diagnóstica (Abramed) Como Estratégia De Competitividade No Setor Privado De Serviços Diagnósticos No Brasil.
  • Roche: Diagnóstica - Roche. https://www.roche.com.br/pt/diagnostica.html
  • DNEDX: Home page. https://dnedx.com.br/
  • Inopat: Conheça um pouco mais sobre nós e sobre nossos serviços. https://www.inopat.com.br/a-inopat/
  • Erba Mannheim Brasil – A ERBA Manheimm oferece soluções de diagnóstico de saúde humana de alto padrão com custo acessível. https://www.erbamanheim.com.br/
  • Percepção de Valor em Serviços de Medicina Diagnóstica. https://www.saudebusiness.com/gestao/percepcao-de-valor-em-servicos-de-medicina-diagnostica
  • Gestão da Inovação em Medicina Diagnóstica: um Estudo de Caso - Biblioteca Digital de Teses e Dissertações da USP. https://www.teses.usp.br/teses/disponiveis/5/5135/tde-10022016-112854/public/Leonardo_Bonato_Perez_Corrigida.pdf
  • Futuro da Saúde: Medicina diagnóstica: o que esperar do setor nos próximos anos. https://futurodasude.com.br/medicina-diagnostica-o-que-esperar-do-setor/
  • A expansão dos laboratórios clínicos no Brasil: desafios para 2025. https://www.acclab.com.br/a-expansao-dos-laboratorios-clinicos-no-brasil-desafios-para-2025/
  • Afip: Afip lança unidade de negócios de medicina diagnóstica. https://www.afip.com.br/afip-lanca-unidade-de-negocios-de-medicina-diagnostica/
  • Afip: O Dia Nacional da Filantropia, celebrado em 20 de outubro, é um bom momento para se observar os ganhos do trabalho realizado por entidades filantrópicas como a Afip Medicina Diagnóstica que, há mais de dez anos, é o maior laboratório de análises clínicas da rede ambulatorial do SUS. A marca pertence à AFIP. https://www.afip.com.br/o-dia-nacional-da-filantropia-celebrado-em-20-de-outubro-e-um-bom-momento-para-se-observar-os-ganhos-do-trabalho-realizado-por-entidades-filantropicas-como-a-afip-medicina-diagnostica-que-ha-mais-de-dez-anos-e-o/
  • Gold Analisa Diagnóstica - Produtos para uso diagnóstico in vitro - Minas Gerais - Brasil. https://goldanalisa.com.br/
  • Medicina SA: Mercado de dispositivos médicos e diagnóstico in-vitro cresceu 57,9%. https://medicinasa.com.br/mercado-dispositivos-medicos/
  • CRM-PB: Anatomia Patológica: já ouviu falar?. https://www.crmpb.org.br/anatomia-patologica-ja-ouviu-falar/
  • FORTA TECH: Equipamentos de diagnóstico e reparo para profissionais. https://fortatech.com.br/equipamentos-de-diagnostico/
  • Histocell: Soluções em Anatomia Patológica. https://histocell.com.br/
  • Terra: Fusões e aquisições no setor de saúde devem crescer este ano, com foco regional, diz consultoria. https://www.terra.com.br/economia/fusao-e-aquisicao/fusoes-e-aquisicoes-no-setor-de-saude-devem-crescer-este-ano-com-foco-regional-diz-consultoria,5156b31a6f66c4244878f249604280cahc8432oq.html
  • Conselho Federal de Medicina: Aumento recorde no total de médicos no País pode ser cenário de risco para a assistência, avalia Conselho Federal de Medicina. https://portal.cfm.org.br/noticias/aumento-recorde-no-total-de-medicos-no-pais-pode-ser-cenario-de-risco-para-a-assistencia-avalia-conselho-federal-de-medicina/
  • Interfarma: Medicina diagnóstica tem papel decisivo na saúde suplementar.
  • Estadão: Fusões e aquisições no setor de saúde disparam no 1º trimestre, diz PwC. https://www.estadao.com.br/economia/fusoes-e-aquisicoes-no-setor-de-saude-disparam-no-1-trimestre-diz-pwc/
  • Shopplab Notícias: O Mercado Brasileiro de Medicina Diagnóstica: um Panorama Atual. https://www.shopplab.com.br/blog/o-mercado-brasileiro-de-medicina-diagnostica-um-panorama-atual/
  • BizNews Brasil: Fusão mexe com mercado de medicina diagnóstica: Fleury se une a Pardini e pode ultrapassar Dasa. https://biznews.com.br/fusaofleuryhermespardini/
  • Saúde Business: Fusões e aquisições no setor de saúde ganham impulso em 2024. https://www.saudebusiness.com/fusoes-e-aquisicoes/fusoes-e-aquisicoes-no-setor-de-saude-ganham-impulso-em-2024